Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07453602 · ClinicalTrials.gov registry record · Phase 1
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
A Phase 1 study of Eczema and Atopic Dermatitis (AD), sponsored by Arcutis Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 125
- Enrollment target
- 1
- Study location
NCT07453602 is a Phase 1 study of Eczema and Atopic Dermatitis (AD) that is actively recruiting participants, run by Arcutis Biotherapeutics. The registered enrollment target is 125 participants, below the 202-participant average among 29 other Eczema trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07453602, a Phase 1 study of Eczema and Atopic Dermatitis (AD), is actively recruiting participants, sponsored by Arcutis Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a first-in-human, Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study evaluating ARQ-234. The study is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARQ-234 in two populations: healthy volunteers and participants with moderate to severe atopic dermatitis (AD). Healthy volunteers will participate in Single Ascending Dose (SAD) Cohorts 1-5. Participants with moderate to severe AD will be enrolled in SAD Cohorts 6-7, Multiple Ascending Dose (MAD) Cohorts, and a Proof-of-Concept (POC) expansion cohort.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL ARQ-234
Study Locations (1)
New Jersey
- Clinical Site 101 - Fair Lawn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2026-03-02 |
| Est. Completion | 2028-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07453602
The ClinicalTrials.gov registry entry for NCT07453602 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 202-participant average among 29 other Eczema trials with a reported enrollment target (38% lower). The listed sponsor is Arcutis Biotherapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Eczema appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07453602 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT07453602 about?
NCT07453602 is a clinical study titled "Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234". This is a first-in-human, Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study evaluating ARQ-234. The study is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARQ-234 in two populations: healthy volunteers and participants wit...
What is the current status of trial NCT07453602?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 125 participants. The study started on 2026-03-02. Estimated completion is 2028-04.
What conditions does trial NCT07453602 study?
This clinical trial studies the following conditions: Eczema, Atopic Dermatitis (AD).
What interventions are being tested in trial NCT07453602?
The interventions under investigation include: Placebo (DRUG), ARQ-234 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07453602?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07453602 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eczema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis
COMPLETED · Phase 1
-
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Flourish: Exploring the Early Infant Gut Microbiome
RECRUITING · NA
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.